In chemical carcinogenicity and drug-safety testing, a cacinogen i s defined as an agent that when administered by an appropriate route causes an increased incidence of tumors in experimental animals as compared to unexposed control animals. Although a carcinogen may cause the appearance of tumors in organs where tumors do not usually occur in a given strain, the usual response is to increase the types of tumors seen spontaneously and to shorten the period of latency. The use of cacinogenesis experiments for research and safety assessment requires properly designed and well-conducted experiments and a knowledge of background data and variations in tumor incidences of control animals. Many factors can influence the reported incidences of spontaneous tumors. These include species, strain, sex, age, and source of the experimental test animal; study duration; extent of the pathology examination; dietary and environmental conditions; qualifications and experience of the study pathologist; diagnostic criteria and nomenclature conventions; and quality assurance and review procedures. This paper discusses several factors which may influence the incidence of tumors in control and test animals, and provides examples to illustrate the potential for these factors to affect the data.
INTRODUCTION
Knowledge of the pathology of spontaneous or natural occurring neoplasms of laboratory animals is essential to their use in carcinogenesis research and testing. Evaluations of experimental results must consider the incidence, type, and behavior of neoplasms in control populations. The use of carcinogenesis experiments for research or safety assessment requires properly designed and wellconducted experiments and a knowledge of background data and variations in tumor incidences of control animals. The detcrrnination of whether a chemical or drug is a carcinogen depends upon one or more of the following criteria: (1) increased tumor incidence of a type seen commonly in control animals; 2) a decrease in the latency of tumor appearance in treated animals compared Presented at the Third International Symposium of the Society of Toxicologic Pathologists. hlay 13-15, 198-1. Arlington, \'A. with control animals; 3) appearance of tumors in organs where tumors do not ordinarily occur or of a tumor type not seen in control animals; and 4) increase in the number of tumors of a specific type per animal when compared to control animals.
Assessment of each of these requires comparisons of results obtained in treated animals to those obtained in controls. Although the concurrent control group is always the most appropriate control group for this comparison, there are certain instances in which the use of historic control information can aid in the overall evaluation of tumor incidence data. Historic control data may be useful to evaluate the significance of rare tumors or a tumor which has a borderline increased incidence relative to concurrent controls. Historic control data are also useful for quality control aspects of a study to determine if concurrent control tumor incidences are consistent with previously reported rates (13,311. Of the many species of laboratory animals TOXICOLOGIC PATHOLOGY used in both experimental carcinogenesis and in testing programs, the rat and mouse are most common. A variety of strains and stocks of rats and mice have been used over the years in carcinogenicity studies. The more common strains of rats used are the inbred F344 (Fischer) and OM (Osborne-Mendel) rat and stocks are random-bred Sprague-Dawley, Wistar, and to a lesser extent Long Evans and Holtzman. Strains and stocks of mice frequently used include the Swiss and related stocks, the inbred Balb/c strain, and C57B1/6N X C3H/HeN)Fl or B6C3Fl hybrid. There are varying amounts of published data on natural diseases and spontaneous tumor rates for each of these strains and stocks of rats and mice ( l , 2 , 6, 7,10, 11, 15,17-19, 21-27, 29, 30, 33, 36) .
Many factors can influence the reported incidences of spontaneous tumors leading to variations in tumor incidences of control animals. Certain of these factors are widely recognized and, consequently, studies are designed to minimize their effect on the data. Major factors include species, strain, sex, age, and source of the experimental test animal, dietary and environmental conditions, as well as, the study duration and extent of the pathology examination. Factors which affect study to study and laboratory to laboratory variations of the incidence of spontaneous tumors are not as easily identified and therefore are more difficult to recognize and control. Among different laboratories, these include environmental conditions, animal husbandry practices, qualifications and experience of pathologists, diagnostic criteria, nomenclature conventions, and quality assurance and review procedures. Since these latter variables are more difficult to define and control, it is more difficult to minimize their effect.
The main purpose of this paper is to discuss several factors which can influence the re-ported incidence of tumors in control and test animals. Only through a thorough appreciation of thes-e factors can appropriate changes be made to study protocols and experimental designs to minimize their effect.
FACTORS CONTROLLED BY STUDY PROTOCOL
Most variables in carcinogenesis experiments are defined by the study protocols thus providing minimal influence on the results of an individual study or test. These include the test animal, the study duration, dietary and laboratory environmental conditions, and the extent of the pathology examination. These variables should be strictly controlled during the duration of each individual study. There may be study to study variations which may affect historic control information, but the conduct of an individual study should strictly minimize differences between concurrent control and test groups. Even though these variables may be controlled for a given study, it is important to understand their potential effect on the incidence of background tumor rates.
Species, Strain, and Sex. Although each species or strain of laboratory animal may develop any tumor type, each has characteristic tumor types that may occur during its normal life span. Some strains have comparatively high incidences of specific tumor types while others have low incidences. The sex of the animal also plays a major role in the development of certain tumors, especially those of the reproductive and endocrine systems. The incidence of tumors in rodents also varies between inbred and random-bred strains. For example, Table I compares the incidence of hepatocellular neoplasms in untreated control B6C3F1 mice from 51 studies in the National Toxicology Program (NTP) (13) and 16 studies compiled by Experimental Pathology Laboratories, Inc. (EPL) for Charles River CD-1 mice. Table I shows that there are marked differences between the incidence of spontaneous hepatocellular neoplasms between the two strains of mice and that the incidence of hepatocellular neoplasms is greater in males than females for both strains. The standard deviation of tumor incidences between studies was greater for hepatocellular neoplasms occurring in BGC3F, mice than for studies with CD-1 mice. This may, in part, be due to the higher incidence of spontaneous liver tumors reported for B6C3F1 mice.
Age and Study Duration. The study duration defined by the study protocol will determine the age of the animal at the time it is killed for pathologic examination. The age of the animal at the time of this examination greatly affects the incidence of many tumors. In most strains of rats and mice, spontaneous tumors are rarely observed in animals less than 1 year of age, with few being seen prior to 18 months. After 18 months, the incidence for all types of tumors increases greatly.
The duration of most carcinogenesis studies is 2 years (24 months) at which time the test animals are killed for pathologic evaluation. The test chemical is usually administered from 6-110 weeks of age (14, 28) . Life span data in the literature are uncommon (2, 6, 23, 27) . Life span studies indicate that the incidence of certain spontaneous neoplasms increase markedly after 110-116 weeks of age. In one study using F344 rats (27) . this was particularly true of subcutaneous mesenchymal neoplasms, mammary gland neoplasms, pancreatic acinar cell neoplasms, and for most endocrine organ neoplasms. This same study also reported that the variety of neoplasms was not greater in animals that were allowed to live out their natural life span than in animals that were killed at approximately 2 years of age. Moreover, no neoplasms occurred in the older rats that were not also found in the 2-year control rats. Similar results were observed in other life span studies which have been published.
Dietary and Laboratory Environmental Conditions. Diet, temperature, humidity, bedding, cage size, cage location, number of animals per cage, and husbandry may effect the incidence of spontaneous tumors. The influence of most of these variables is not well-understood; therefore, they are strictly controlled by the study protocol to minimize their effect within a given experiment.
Dietary restriction has been shown to re-duce the incidence of mammary tumors in Sprague-Dawley rats. Conversely, increasing the lipid component of a diet has been shown to increase the incidence of mammary tumors in the rat (3) . Similarly, decreased incidences of mammary fibroadenomas observed in F344 rats from NTP feeding studies were clearly associated with decreases in weight gain (12) . Influence of the diet has been associated with the incidence of neoplasms in various other organs, particularly the pancreas, liver, and colon. The influence of other environmental factors has not been extensively studied. The nutritional status, lighting, and stress due to handling or method of housing may alter endocrine patterns thus affecting the development of spontaneous tumors. Animal husbandry may influence the pattern of spontaneous tumors. The existence of infectious or noninfectious diseases can affect the background incidence of tumors either by altering the homeostasis of the animal or by shortening the life span. Environmental contaminants in the food, water, air, or bedding may alter the pattern of tumor development. Since these factors are not completely understood, concurrent control animals must be included in all studies and need to be housed and handled identically with the treated groups (3, 28) .
Extent of Pathology Examination. The extent of the pathology examination should be clearly and completely defined in the study protocol to limit differences in tumor incidences which may result from either the gross necropsy examination or histologic techniques used to prepare the tissue sections. The incidence of spontaneous or induced tumors observed in specific tissues can vary greatly depending on the pathology protocols. Necropsy protocols and tissue sampling techniques may differ between laboratories or within a laboratory from study to study, thus affecting the incidence of tumors in a historic control data base.
Protocols based only on gross findings may furnish erroneous tumor incidences. Many small tumors in rodents, especially in endocrine organs and parenchymal organs such as the lung and liver, are not grossly visible at the time of necropsy examination (9, 16). Thus, if only gross tumors were sectioned, many smaller ones would not be identified. Likewise, some tissues which are not routinely included in pathology protocols but are TOXICOLOGIC PATHOLOGY examined only when grossly abnormal are likely to have erroneously low incidences of reported tumors. This is particularly true of Harderian gland neoplasms in mice. The historic control incidence of Harderian gland neoplasms in B6C3F1 mice in the National Toxicology Program is approximately 2.2% in male and 1.3% in female mice (13) based on histologically confirmed gross findings. In two NTP bioassay studies in which histologic examination was conducted on all Harderian glands, the incidence of these tumors in controls was 12.0% in male and 6.0% in female mice (34).
The procedures followed for tissue sampling and techniques used for tissue sectioning can effect the incidence of neoplasms observed. The more tissue and tissue sections which are prepared, the greater the number of small tumors which will be identified. These differences have been demonstrated by comparing the results of serial sectioning and complete sectioning of tissues with results obtained from random sections which were routinely evaluated.
In 1963, Thompson and Hunt (32) investigated the incidence rate of several types of neoplasms in the thyroid gland, adrenal gland, pituitary gland, ovary, uterus, brain, and testes of 177 Sprague-Dawley rats using serial section techniques. The results were compared with incidences previously reported for the same group of rats as determined by examination of random single tissue sections ( Table 11 ). The number of tumors observed by random single tissue sections versus serial tissue sections were 9 versus 55 light cell [C-cell) adenomas of the thyroid gland, 7 versus 11 pheochromocytomas of the adrenal gland, 5 versus 8 adenomas of the pituitary gland, 0 versus 1 papillary adenocarcinoma of the ovary, and 1 versus 6 endometrial polyps of the uterus. No additional tumors were observed in the brain or testes.
In a recently completed study conducted at Experimental Pathology Laboratories, Inc. for the National Toxicology Program, the incidence of proliferative lesions of the exocrine pancreas in male F344 rats was compared between random sections and sections of the entire pancreas. This study was conducted on untreated control groups (Table 111) and vehicle (corn oil) control groups (Table  IV) from four studies. The number of proliferative acinar cell lesions was increased by examining the entire pancreas when compared to random sections routinely examined. This increase was more notable in the vehicle (corn oil) control groups than in t h e untreated control groups.
FACTORS INDEPENDENT OF STUDY PROTOCOL
Although many variables affecting a carcinogenesis study can be strictly defined and controlled by the study protocol, a few factors that influence the study results are relatively independent of the study protocol. These variables include the training and experience of the study pathologist, the criteria and consistency used to render morphologic diagnoses, various nomenclature conventions for the same or similar neoplasms, and the quality assurance and review procedures used to verify the results. Training and Experience of the Study Pathologist. The diagnosis of neoplasms and lesions in experimental animals is a difficult task. Considerable training, skill, and experience are necessary to properly conduct the gross and histopathologic examinations of tissues from a study. The training, experience, and background of individual pathologists varies widely. Pathologists receive training through a variety of avenues including formal postdoctoral and residency training programs. Many of these programs do not adequately address the pathology of laboratory animals or toxicologic pathology. Therefore, much of the expertise of a pathologist in the field of toxicologic pathology is gained by practical experience and continuing education from reading current literature and participation in meetings and workshops.
The training and qualifications of a pathologist can be judged by professional degrees, be it DVM, PhD, or MD, and by certification either by the American College of Veterinary Pathologists (ACVP) or the College of American Pathologists (CAP). Formal degrees or certification alone do not guarantee the ability of a pathologist to conduct histopathologic examinations of studies designed to evaluate the potential toxicity or carcinogenicity of a drug or chemical. In addition to being welltrained, the qualifications necessary to be a toxicologic pathologist include experience examining tissues from laboratory animals, familiarity with tumors, and lesions of laboratory animals, as well as their classification, and the ability to generate and compile data in a consistent manner.
Since pathology is mainly a subjective science, exact measurements are not always available to provide an unequivocal diagnosis of a particular lesion. Diagnoses of pathologic lesions and their implications may differ among pathologists depending on each individual's background, training, and experience. This diversity of opinions among pathologists may lead to disagreements in tumor diagnoses and thus tumor incidences. These disagreements may be accounted for by (i) hyperplasia versus neoplasia for small lesions or neoplasms about which the bio-logic progression or natural history is not known, (ii) the classification of benign versus malignant neoplasms, (iii) unusual or rare lesions with uncertain histogenesis, and (iv) differences in diagnostic criteria or terminology for the same lesion. In some instances, these differences result from errors in diagnoses. These may involve tumor diagnoses for lesions which are not tumors or nontumor diagnoses for lesions which are obviously tumors. These errors in diagnoses may result from unfamiliarity with expected spontaneous neoplasms for the test animal, lack of experience, or careless work.
Errors in the diagnoses of neoplasms most commonly result from lack of experience with and knowledge of commonly occurring neoplasms in the test animal, rather than from careless work. Several of these types of errors have been identified during the review of pathology data from NTP carcinogenesis bioassay studies; for instance, diagnosis of mesothelioma of the tunica vaginalis as granulomatous inflammation and multifocal granulomas in the lung as metastatic interstitial cell carcinoma from the testis in male F344 rats. In female BtiC3F, mice, myelofibrosis of the sternal marrow cavity has been diagnosed as hemangiosarcoma and primary lung tumors in mice of both sexes have been diagnosed as metastatic neoplasms from a variety of primary sites. Table V demonstrates the type of erroneous data that may result from inexperience or lack of knowledge concerning commonly occurring neoplasms in the species and strain of test animal. The NTP historic control incidences of primary lung tumors in male and female BGC3F1 mice are 12.1% and 5.5% for alveolar bronchiolar adenomas and 5.1 % and 2.0% for alveolar bronchiolar carcinomas. In the study summarized in Table V , no primary lung tumors were diagnosed by the original pathologist. The alveolar bronchiolar adenomas and carcinomas observed during the review of this study had been originally diagnosed as either metastatic hepatocellular carcinomas or metastatic mammary gland adenocarcinomas. I n mice that did not have a primary liver or mammary neoplasm, the lung neoplasms were diagnosed as metastatic carcinomas without indicating the site of the primary tumor.
The potential effect of a pathologist's lack of experience and familiarity with spontaneous neoplasms is obvious. Other problems which may occur in the diagnoses of neoplasms may result from a lack of knowledge concerning normal anatomic structures which are unique to laboratory rodents and the inability of some pathologists to distinguish between artifacts produced during necropsy and slide preparation from proliferative lesions. A few unique anatomic differences between laboratory rodents and other domestic animals frequently present difficulty. The most common of these are the clitoral, preputial, and external auditory sebaceous glands (Zymbal glands). Artifacts due to tissue handling or oblique tissue sections most frequently present diagnostic interpretative problems when they involve the urinary bladder or forestomach. Diagnostic Criteria. Differences in diagnostic criteria which exist among pathologists can affect the incidence of tumors reported in a study. The most significant differences, and possibly the most difficult to resolve, involve the differentiation between focal (nodular) hyperplasia and benign neoplasia (adenoma). Focal or diffuse hyperplasia is frequently the earliest proliferative lesion observed in an organ or tissue. Focal lesions may enlarge and become nodular with compression of the adjacent parenchyma. This lesion is considered to be nodular hyperplasia or hyperplastic nodule by some. Others consider a circumscribed nodular proliferation of cells which compress the adjacent tissues to be an adenoma. These differences will have lesser impact on data interpretation if clear diagnostic descriptions are given and if consistency in diagnoses is maintained between control and test groups. This allows others to make informed analysis of the lesions. examined)
Disagreements concerning hyperplasia versus benign neoplasia for small lesions or lesions for which the biologic progression is not well-understood will likely continue to exist. However, this distinction should not be taken lightly since the determination of whether a drug or chemical is considered to be a potential carcinogen often depends upon a pathologist's ability to consistently make this differentiation. Depending on the specific set of criteria for diagnosing a lesion, wide variations may occur in the incidence of tumors and hyperplasia among different pathologists. Table VI is an example of how different diagnostic criteria effected the incidence of proliferative lesions of the C-cells in the thyroid gland of untreated control rats in a recent NTP carcinogenicity study. The original diagnoses were made using criteria established by DeLellis et a1 (8) that proliferative lesions of the C-cells were considered to be hyperplastic until there was infiltration of the basal lamina of the thyroid follicle.' Infiltration of the basal lamina was considered to be evidence of malignancy and the lesion was classified as a carcinoma. This set of criteria does not recognize an adenoma of the C-cells but considers all neoplasms as at least potentially malignant (8). The reviewing pathologist applied criteria established by the National Toxicology Program and described by Boorman and DeLellis in 1983 (4). These criteria separate proliferative C-cell lesions into hyperplasia, adenoma, and carcinoma. Many of the lesions which were diagnosed as nodular hyperplasia using previous criteria are considered to represent benign neoplasms using the NTP criteria.
Nomenclature Conventions. Numerous nomenclature conventions and various defined sets of terminology have been proposed over the years in the hopes of simplifying, generalizing, or otherwise making more meaningful the classification of rodent neoplasms. Most of these schemes represent similar thoughts concerning the nature of specific rodent tumors expressed in a different manner by various investigators. The confounding result has been that the literature, and frequently data from studies, contain numerous synonyms for the same lesion. This has been especially true for the classification of liver neoplasms in rats and mice, as well as many other rodent tumors. Tables VII-IX list a few of the synonyms which have been used to classify hepatocellular adenomas in mice, adrenal pheochromocytomas in rats, and thyroid C-cell adenomas in rats.
Similar problems have been encountered using multiple topographies for the diagnosis of a specific lesion. This is often compounded when synonymous morphologic diagnoses are also used. This type of problem is occasionally observed in the diagnosis of: forestomach, papilloma and squamous cell pap- illoma; stomach, papilloma all in the same study. These types of data result from a pathologist's lack of appreciation for the deliberate and consistent generation of data that is necessary to properly conduct histopathologic examination and evaluation of tissues from animals used in carcinogenicity and safety assessment studies. Quality Assurance and Review Procedures. Toxicology studies are expensive and timeconsuming. They often provide essential evidence used in the regulatory decision-making process that concerns the use of and human exposure to many economically important compounds and chemicals. Individuals entrusted to conduct these studies must have adequate quality control procedures to assure the scientific validity of the studies and in particular the pathology data. Organizations that utilize these data should have quality assurance and review procedures to verify the results and to confirm the scientific validity of the data used in the decision-making process.
Informal review procedures are commonly implemented either by individual pathologists or by groups of pathologists within a laboratory prior to submission of study results. These may range from consultation on an individual lesion to a blind review of lesions in potential target organs. Formal quality assurance and review procedures have been recommended for animal toxicologic studies with expected broad socioeconomic impact (5, 20, 35) . To date, only the National Toxicology Program has implemented formal quality assurance and review procedures as a routine integral component of the histopathology protocol. These procedures were implemented by the National Cancer Institute as described by Ward et al (35) and have been expanded by the National Toxicology Program to include monitoring and auditing of at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from the pathology data for on-going toxicity and carcinogenity studies (5) .
The quality assurance program conducted by the NTP has been established to review the accuracy of the study pathologist's diagnoses. This program utilizes independent pathologists, with extensive experience of the lesions in the strains of rodents used, to assess the original histopat hologic diagnoses. Disagreements in diagnosis and other inconsistencies in the data are examined by a panel of toxicolgic pathologists (NTP Pathology Working Group) who make recommendations for resolutions.
During the NTP quality assurance review, tissues which are routinely examined microscopically include all neoplasms diagnosed in the study, all potential target organ tissues, and all slides from a random sample of animals in each dose group (usually 10%). This microscopic review may also include all tissues with tumor incidences which are unusually low or high in the control groups. During this review, the reviewing pathologist's diagnoses are compared with the study pathologist's diagnoses and all disagreements are noted. The reviewing pathologist prepares a report of all discrepancies in diagnoses and an accompanying set of slides containing all target tissues and tissues with noted discrepancies to be reviewed by the NTP Pathology Working Group. This panel of pathologists reviews representative slides of the treatment-related lesions in target organs and discrepancies noted in the quality assurance report. When there is a difference of opinion between the study pathologist and the NTP Pathology Working Group, the slide is returned to the study pathologist for reexamination. After the study pathologist reviews the slides in question, a final pathology table is produced and a final pathology narrative is prepared by the study pathologist. At this point, the pathology is considered complete and drafting of the NTP technical report proceeds. Following this intensive pathology review process, a n ad hoc peer review panel (NTP Board of Scientific Counselors) and other interested parties can examine and utilize the information-in the technical report with confidence that all lesions have been accounted for, accurately and consistently sampled, recorded, tabulated, interpreted, and evaluated in the final report (14) .
A potential weakness in the data from toxicology and carcinogenicity studies is the rel-ative reliability of gross and histopathology data. While erroneous observations occurring during the antemortem phase of a study may be either verified or refuted by gross and histopathology data, similar assurances are not available for the pathologist. A lesion overlooked at necropsy may be discarded or never sectioned for microscopic examination. A lesion missed or incorrectly diagnosed by the histopathologist may remain forever uncorrected. Only through vigorous and thorough review of the pathology data can its reliability be verified. This review will help minimize the influence of many of the variables in a study that are not and cannot be strictly defined and controlled by the study protocol.
DISCUSSION
Testing a drug or chemical for carcinogenicity in animals is an essential step in evaluating its carcinogenic potential for humans. Such evaluation is based on results from experimental studies in laboratory animals. The rat and the mouse are usually used in carcinogenicity studies, since they are known to be responsive to many of the known carcinogenic agents, have a relatively short life span, and are commonly used in the laboratory for pharmacology and toxicology studies. Evaluation of carcinogenicity experiments for research and safety assessment requires properly designed and well-conducted studies which result in the comparison of tumor incidences between control and experimental animals. The most appropriate comparison is with concurrent control incidences of tumors, but historic control incidences are sometimes useful in the assessment of the results obtained in carcinogenicity studies.
In addition to spontaneous tumors occurring in rodents, anatomic changes due to aging may create problems in interpretation for the pathologist, biosta tis tician, toxicologist, and others using the data. The appearance of tumors in the control and test species assumes major significance in the interpretation and evaluation of the data. Many factors can influence the reported incidence of tumors. A few can be limited by strict adherence to the study protocol, while others are Iess well-understood and not as easily controlled. The study pathologist must have a thorough knowledge of the pathology of tumors and other naturally occurring lesions in laboratory animals and an appreciation of the many variables that may affect the data for a study. Additionally, individuals involved in review, interpretation, or evaluation of the study results and those who use the data to make regulatory decisions concerning a drug or chemical must also have an in-depth appreciation of tumor incidences in control and exposed animaIs and of the potential effects of variables associated with data resulting from these studies. 
DISCUSSION OF THE PAPER
DR. SWARM: I'd like to deviate from the schedule at this point. I suggest that we have an 8-min period for discussion and then a 10min break. That will put us about 15 min behind our schedule, and I think we can tolerate that for the afternoon.
DR. PAYNE: Your last statement obviously isn't true. You said that the regulatory agency must have people who are knowledgable about the neoplasms of laboratory animals. At the risk of offending people in the FDA, I don't believe that there is anyone in the Food and Drug Administration who purports to be an expert on the histopathology of laboratory animals. I would like to be corrected if that is not true. DR. HIGGINSON: Although everybody knows what the word spontaneous means in this sense, I would prefer to use a less controversial word such as background incidence.
DR. HARDISTY: I think you are probably right. I was at a meeting about a year ago, and one of the pathologists there objected to the use of the term spontaneous neoplasms as well. He preferred to consider "spontaneous" neoplasms those for which we haven't determined the carcinogen as yet. DR. HOMBURGER: The incidence of spontaneous tumors or base-line tumors in rats and mice is certainly a confounding factor and a most annoying one. I'm somewhat surprised that you did not mention at all that there are species with very low incidences of so-called spontaneous tumors, particularly in the case of Syrian hamster. None of the tumors that you usually induce with carcino-gens occur. When we have an incidence of lymphomas of about 13%, an incidence of adrenal tumors of maybe 12-13%, and practically no other background tumors, then we have a very good model that deserves to be investigated. There is no correlation between the spontaneous incidences, the susceptibility of the animal to carcinogens, and the induction of tumors. I am utterly surprised and have been for the last 25 years that the National Toxicology Program doesn't look at that. DR. VESSELINOVITCH: I'm not clear. I'm a little bit confused when you use the term synonyms. Under synonym you have hyperplasia and cancer. Synonyms should be words that describe or have the same meaning. You mean to say, if I read straight forward what you said, that hyperplasia equates to carcinoma? DR. HARDISTY: No, I didn't mean to imply that at all. What I was trying to demonstrate there was that the same lesion has been called hyperplasia by some and adenoma by others. The lists that I presented very briefly, near the end of the talk, are lists of terms which have been used to describe those lesions in the literature over the years.
DR. (unidentified): One question-do you review procedures? Is the first reading done by parapathologists, which was started in NCTR in Pine Bluff, or by qualified pathologists?
DR. HARDISTY: The first reading is done by qualified pathologists, many of which are board certified veterinary pathologists. None of the first readings are done by parapathologists.
